![](/images/graphics-bg.png)
Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries
Joint Authors
Zhao, Jingmin
Zheng, Su-Jun
Qian, Xiangjun
Wang, Leijie
Yao, Mingjie
Guan, Guiwen
Wen, Xiajie
Zhang, Ling
Xu, Qiang
Chen, Xiangmei
Duan, Zhongping
Lu, Fengmin
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-09-17
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Background and Aim.
Serum Golgi protein 73 (GP73) is a promising alternative biomarker of chronic liver diseases, but most data are from patients with HBV infection rather than HCV.
Materials and Methods.
Two independent cohorts of chronic hepatitis C (CHC) patients from the 5th Medical Centre of the Chinese PLA General Hospital (n=174) and Beijing Youan Hospital (n=120) with different histories of HCV infection were enrolled.
The correlations between serum GP73 and other biochemical indices, as well as its correlations with different stages of liver disease progression, were investigated.
The receiver operating characteristic (ROC) curve was employed to evaluate the diagnostic potential of serum GP73 for liver necroinflammation and fibrosis, and comparisons of the diagnostic efficiency with traditional indices of hepatic liver injuries were further investigated.
Results.
Levels of serum GP73 were found significantly elevated in patients with moderate to severe inflammatory grade (G≥2) and/or with advanced fibrotic stages (F≥3) in both cohorts (P<0.05, respectively), as compared to those with a normal or mild liver lesion.
Further ROC analysis demonstrated that serum GP73 was comparable to serum ALT and AST in diagnosing the liver necroinflammation grade at G≥2, but its diagnostic values for advanced fibrosis (F≥3) and cirrhosis (F=4) were limited when compared to APRI and FIB-4, and FIB-4 exhibited the best performance.
Notably, an obvious elevation of serum GP73 was observed after patients received PEG-IFN and ribavirin treatment.
Conclusions.
Serum GP73 is an important biomarker in evaluating and monitoring the disease progression including liver necroinflammation and fibrosis in patients with chronic HCV infection, but the value is limited for diagnosing advanced fibrosis and cirrhosis in comparison with APRI and FIB-4.
American Psychological Association (APA)
Qian, Xiangjun& Zheng, Su-Jun& Wang, Leijie& Yao, Mingjie& Guan, Guiwen& Wen, Xiajie…[et al.]. 2019. Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries. Disease Markers،Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1147124
Modern Language Association (MLA)
Qian, Xiangjun…[et al.]. Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries. Disease Markers No. 2019 (2019), pp.1-10.
https://search.emarefa.net/detail/BIM-1147124
American Medical Association (AMA)
Qian, Xiangjun& Zheng, Su-Jun& Wang, Leijie& Yao, Mingjie& Guan, Guiwen& Wen, Xiajie…[et al.]. Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries. Disease Markers. 2019. Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1147124
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1147124